Predict your next investment

Venture Capital
biomedicine.ch

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Funds

1

About Biomedicine

International BM Biomedicine Holdings is an investment firm which invests in leading technology-based, research-oriented biotechnology companies in the pharmaceutical area. The firm uses Global Biomedical Partners as its exclusive investment advisor to perform due diligence and make recommendations that IBMH acts on.

Biomedicine Headquarter Location

Nauenstrasse 41

Basel, 4002,

Switzerland

41 61 270 8210

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Biomedicine

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Biomedicine in 2 CB Insights research briefs, most recently on Jul 31, 2019.

Latest Biomedicine News

"Developing Biomedicine in the Greater Bay Area: Opportunities and Challenges" Summit Held in Shenzhen

Oct 20, 2021

News provided by Share this article Share this article SHENZHEN, China, Oct. 20, 2021 /PRNewswire/ -- On October 16, a summit titled "Developing Biomedicine in the Greater Bay Area: Opportunities and Challenges" was successfully held in Shenzhen, China. Top leaders and experts from the government, industry, academia and medical services gathered to explore opportunities and challenges of developing the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area under the current economic and international climate. Global Launch Ceremony of Cheerland Bio-CDMO This Summit was organized by the Office of National Brand Project of Xinhua News Agency, co-organized by China News Development Shenzhen, CFBond.com and Cheerland Biologics, sponsored by Shenzhen Investment Holdings Capital, with support from Shenzhen Dapeng New District Management Committee. Mr. Li Bin, Deputy Director of National Health Commission (NHC) and a member of the Managing Party Council of NHC, headlined the delegate of government officials attending the Summit. Mr. Li applauded the Centralized Volume-based Procurement of Drug Consumables, a major policy of the CPC Central Committee's drug reform efforts starting from 2020. Thanks to this new policy, China's new drug R&D and innovation capability, as well as quality assurance, supply capacity and clinical use have all been remarkably improved. Mr. Gong Xixiang, a member of the Managing Party Council and Secretary General of Xinhua News Agency, pointed out that Shenzhen, as one of the core engine cities in the Guangdong-Hong Kong-Macao Greater Bay Area, has aspired to become a leader and innovation hub for biomedicine. Mr. Xu Jianping, Director of the Regional Opening Department of the National Development and Reform Commission, urged the Greater Bay Area to play a leading role in developing the Health Silk Road, for the benefit of China and other countries involved. Mr. Liu Ruyin, Founder and Chairman of Cheerland Biologics, expressed that Cheerland, headquartered in Shenzhen, has been striving to become a regional and national leader in biotechnology. It has built a world-class management team with international executives, led by Mr. Michael Garvey, President and Managing Director of the Board. Cheerland also established a biomedicine eco-system consisted of diagnostic labs based on gene sequencing, a drug development platform and pipelines, medical services, and now CDMO (contract development and manufacturing organization). Cheerland is building the first large-scale biologics CDMO (Bio-CDMO) base in China, aiming to provide international standard, low cost, commercial scale Bio-CDMO services to global biotech clients. The global launch ceremony of Cheerland Bio-CDMO, and a service contract signing ceremony were held at the Summit. A panel featuring academicians and industry leaders discussed how the Greater Bay Area can promote high-quality development of the biomedical industry under the current economic and geopolitical climate. About Cheerland Biologics Cheerland Biologics, a co-organizer of the Summit, was established in Shenzhen in April 2016 and elected into the National Brand Project of Xinhua News Agency in April 2021. Cheerland aims to lower significantly the cost of biologics and make biomedicine accessible to everyone, through technological innovation and providing large-scale manufacturing services to the global biotech industry. Image Attachments Links:

Biomedicine Investments

2 Investments

Biomedicine has made 2 investments. Their latest investment was in Artemis Pharmaceuticals as part of their Series B on April 4, 2000.

CBI Logo

Biomedicine Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/5/2000

Series B

Artemis Pharmaceuticals

$12.56M

No

1

9/16/1998

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/5/2000

9/16/1998

Round

Series B

Series A

Company

Artemis Pharmaceuticals

Subscribe to see more

Amount

$12.56M

$99M

New?

No

Subscribe to see more

Co-Investors

Sources

1

10

Biomedicine Portfolio Exits

1 Portfolio Exit

Biomedicine has 1 portfolio exit. Their latest portfolio exit was Artemis Pharmaceuticals on April 01, 2001.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/1/2001

Acquired

Undisclosed Investors

1

Date

4/1/2001

Exit

Acquired

Companies

Valuation

Acquirer

Undisclosed Investors

Sources

1

Biomedicine Fund History

1 Fund History

Biomedicine has 1 fund, including Biomedicine LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/1/2000

Biomedicine LP

Buyouts & Acquisitions

$73.53M

1

Closing Date

1/1/2000

Fund

Biomedicine LP

Fund Type

Buyouts & Acquisitions

Status

Amount

$73.53M

Sources

1

Biomedicine Team

4 Team Members

Biomedicine has 4 team members, including current Chief Executive Officer, Patrick Weber.

Name

Work History

Title

Status

Patrick Weber

Chief Executive Officer

Current

Richard J Dold

Chief Executive Officer

Former

Stefan Ryser

Chief Executive Officer

Former

Michael E Meyers

Managing Partner

Former

Name

Patrick Weber

Richard J Dold

Stefan Ryser

Michael E Meyers

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Managing Partner

Status

Current

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.